Search Results - "He, Cixin S."

Efficacy and safety of lenvatinib plus pembrolizumab vs sunitinib in the East Asian subset of patients with advanced renal cell carcinoma from the CLEAR trial by Rha, Sun Young, Choueiri, Toni K., Matveev, Vsevolod B., Alyasova, Anna, Hong, Sung‐Hoo, Gordoa, Teresa Alonso, Gurney, Howard, Bjarnason, Georg A., Buchler, Tomas, Pedrazzoli, Paolo, Takagi, Toshio, Park, Se Hoon, Lee, Jae Lyun, Perini, Rodolfo F., He, Cixin S., McKenzie, Jodi A., Eto, Masatoshi

“…In the CLEAR trial, lenvatinib plus pembrolizumab met study endpoints of superiority vs sunitinib in the first‐line treatment of patients with advanced renal…”
Get full text

Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale by Grünwald, Viktor, Powles, Thomas, Choueiri, Toni K, Hutson, Thomas E, Porta, Camillo, Eto, Masatoshi, Sternberg, Cora N, Rha, Sun Young, He, Cixin S, Dutcus, Corina E, Smith, Alan, Dutta, Lea, Mody, Kalgi, Motzer, Robert J

“…Lenvatinib plus everolimus is approved for the treatment of advanced renal cell carcinoma (RCC) after one prior vascular endothelial growth factor-targeted…”
Get full text

Dose-expansion part of a phase 1b global study of E7386 in combination with lenvatinib (LEN) in patients (pts) with hepatocellular carcinoma (HCC) and other solid tumors including endometrial cancer (EC) by Lee, Jung-Yun, Ryoo, Baek-Yeol, Kim, Jin Won, Cheng, Ann-Lii, Finn, Richard S., Hasegawa, Kosei, Makker, Vicky, Kudo, Masatoshi, Miller, David Scott, Merle, Philippe, Ulahannan, Susanna Varkey, Hosaka, Tetsuya, Sahara, Takatoshi, He, Cixin S., O'Hara, Karen, Dutta, Lea, Tamai, Toshiyuki, Ikeda, Masafumi

“…TPS3169 Background: E7386, a first-in-class anticancer agent, inhibits protein-protein interaction between β-catenin and the CREB-binding protein, thus…”
Get full text

Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC) by Motzer, Robert J., Porta, Camillo, Eto, Masatoshi, Powles, Thomas, Grünwald, Viktor, Hutson, Thomas E., Alekseev, Boris, Rha, Sun Young, Merchan, Jaime R., Goh, Jeffrey C., Kapoor, Anil, De Giorgi, Ugo, Melichar, Bohuslav, Hong, Sung-Hoo, Gurney, Howard, Rodriguez-Lopez, Karla, He, Cixin S., Okpara, Chinyere, McKenzie, Jodi, Choueiri, Toni K.

“…4502 Background: In the phase 3 CLEAR trial, L+P showed clinically meaningful and statistically significant benefits in PFS (primary endpoint) and OS, and…”
Get full text